DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D

Anagnostou, 2020, Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis, Lancet Haematol., 7, e816, 10.1016/S2352-3026(20)30277-5 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134 Mohty, 2019, CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives, Leukemia, 33, 2767, 10.1038/s41375-019-0615-5 Ghahri-Saremi, 2021, Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors, Front. Immunol., 12, 738456, 10.3389/fimmu.2021.738456 Johnson, 2021, Rationally designed transgene-encoded cell-surface polypeptide tag for multiplexed programming of CAR T-cell synthetic outputs, Cancer Immunol. Res., 9, 1047, 10.1158/2326-6066.CIR-20-0470 Rousso-Noori, 2021, P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas, Nat. Commun., 12, 3615, 10.1038/s41467-021-23817-2 Rezvani, 2017, Engineering natural killer cells for cancer immunotherapy, Mol. Ther., 25, 1769, 10.1016/j.ymthe.2017.06.012 Lanier, 1998, NK cell receptors, Annu. Rev. Immunol., 16, 359, 10.1146/annurev.immunol.16.1.359 Raulet, 1995, Natural killer cell receptors: the offs and ons of NK cell recognition, Cell, 82, 697, 10.1016/0092-8674(95)90466-2 Biassoni, 2008, Natural killer cell receptors, Adv. Exp. Med. Biol., 640, 35, 10.1007/978-0-387-09789-3_4 Dhar, 2018, NKG2D and its ligands in cancer, Curr. Opin. Immunol., 51, 55, 10.1016/j.coi.2018.02.004 Liu, 2019, Role of NKG2D and its ligands in cancer immunotherapy, Am. J. Cancer Res., 9, 2064 González, 2008, NKG2D ligands: key targets of the immune response, Trends Immunol., 29, 397, 10.1016/j.it.2008.04.007 Lanier, 2015, NKG2D receptor and its ligands in host defense, Cancer Immunol. Res., 3, 575, 10.1158/2326-6066.CIR-15-0098 Markiewicz, 2005, Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation, J. Immunol., 175, 2825, 10.4049/jimmunol.175.5.2825 Groh, 2001, Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells, Nat. Immunol., 2, 255, 10.1038/85321 Dargel, 2015, T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice, Gastroenterology, 149, 1042, 10.1053/j.gastro.2015.05.055 Ye, 2015, Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments, J. Hematol. Oncol., 8, 59, 10.1186/s13045-015-0156-y Miao, 2021, Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors, Front. Immunol., 12, 687822, 10.3389/fimmu.2021.687822 Kirtane, 2021, Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead, J. Immunother. Cancer, 9, e002723, 10.1136/jitc-2021-002723 Yu, 2021, Immunotherapy for glioblastoma: current progress and challenges, Front. Immunol., 12, 676301, 10.3389/fimmu.2021.676301 Zhao, 2019, Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia, J. Hematol. Oncol., 12, 17, 10.1186/s13045-019-0705-x Yang, 2019, T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells, J. Immunother. Cancer, 7, 171, 10.1186/s40425-019-0642-9 Sentman, 2014, NKG2D CARs as cell therapy for cancer, Cancer J., 20, 156, 10.1097/PPO.0000000000000029 Sun, 2019, Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells, Cancer Immunol. Res., 7, 1813, 10.1158/2326-6066.CIR-19-0026 Curio, 2021, A summary of current NKG2D-based CAR clinical trials, Immunother. Adv., 1, ltab018, 10.1093/immadv/ltab018 Baumeister, 2019, Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma, Cancer Immunol. Res., 7, 100, 10.1158/2326-6066.CIR-18-0307 Yang, 2013, Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity, Arch. Med. Sci., 2, 323, 10.5114/aoms.2013.34413 Paczulla, 2019, Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion, Nature, 572, 254, 10.1038/s41586-019-1410-1 Schmudde, 2008, Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells, Cancer Lett., 272, 110, 10.1016/j.canlet.2008.06.027 Valés-Gómez, 2008, Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors, Cancer Res., 68, 1546, 10.1158/0008-5472.CAN-07-2973 Abruzzese, 2016, Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay, J. Hematol. Oncol., 9, 134, 10.1186/s13045-016-0362-2 Lai, 2018, Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells, Leukemia, 32, 801, 10.1038/leu.2017.249